Efficacy and immune-related adverse event associations in avelumab-treated patients

BACKGROUND: Adverse events (AEs) of special interest that arise during treatment with immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to be associated with improved clinical outcomes. We analyzed patients treated with avelumab from the JAVELIN Solid Tumor and M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Kelly, Karen, Manitz, Juliane, Patel, Manish R, D’Angelo, Sandra P, Apolo, Andrea B, Rajan, Arun, Kasturi, Vijay, Speit, Isabell, Bajars, Marcis, Warth, John, Gulley, James L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7682456/
https://ncbi.nlm.nih.gov/pubmed/33219092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001427
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados